rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
26
|
pubmed:dateCreated |
1997-1-24
|
pubmed:abstractText |
The preceding papers of this series detail the development of functionalized indole-3-acetamides as inhibitors of hnps-PLA2. We describe here the extension of the structure-activity relationship to include a series of indole-3-glyoxamide derivatives. Functionalized indole-3-glyoxamides with an acidic substituent appended to the 4- or 5-position of the indole ring were prepared and tested as inhibitors of hnps-PLA2. It was found that the indole-3-glyoxamides with a 4-oxyacetic acid substituent had optimal inhibitory activity. These inhibitors exhibited an improvement in potency over the best of the indole-3-acetamides, and LY315920 (6m) was selected for evaluation clinically as an hnps-PLA2 inhibitor.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
0022-2623
|
pubmed:author |
pubmed-author:AsayJ LJL,
pubmed-author:CENEKRR,
pubmed-author:CarlsonD GDG,
pubmed-author:ChirgadzeN YNY,
pubmed-author:ClawsonD KDK,
pubmed-author:DillardR DRD,
pubmed-author:DraheimS ESE,
pubmed-author:HartleyL WLW,
pubmed-author:JohnsonL MLM,
pubmed-author:JonesN DND,
pubmed-author:McKinneyE RER,
pubmed-author:MihelichE DED,
pubmed-author:OlkowskiJ LJL,
pubmed-author:SchevitzR WRW,
pubmed-author:SmithA CAC,
pubmed-author:SnyderD WDW,
pubmed-author:SommersC DCD,
pubmed-author:WeryJ PJP
|
pubmed:issnType |
Print
|
pubmed:day |
20
|
pubmed:volume |
39
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
5159-75
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
|
pubmed:year |
1996
|
pubmed:articleTitle |
Indole inhibitors of human nonpancreatic secretory phospholipase A2. 3. Indole-3-glyoxamides.
|
pubmed:affiliation |
Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA.
|
pubmed:publicationType |
Journal Article
|